Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.0
4.8
Journals
JFB
Special Issues
Biomaterials for Translational Medicine
share announcement

Biomaterials for Translational Medicine

A special issue of Journal of Functional Biomaterials (ISSN 2079-4983). This special issue belongs to the section "Biomaterials for Drug Delivery".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 2256

Special Issue Editors

Dr. Maria Chiara Cristiano

E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy
Interests: transdermal drug delivery; rheology; translational medicine; nanomedicine; nanotechnology
Prof. Dr. Massimo Fresta

E-Mail Website
Guest Editor
Department of Health Sciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S. Venuta”, Viale Europa, 88100 Catanzaro, Italy
Interests: targeted drug delivery systems; supramolecular aggregates; liposomes; vesicles; nanoparticles; nanocapsules; brain delivery; tumor delivery; nanomedicine; pharmaceutical nanotechnology; macromolecule functionalization

Special Issue Information

Dear Colleagues,

Translational medicine was born from the idea to convert promising scientific findings in medical application. The aim of translational medicine is to exploit experimental investigations, coming from research laboratory and clinical studies, to achieve easier prediction, prevention, diagnosis and, of course, the efficacious therapeutic treatment of a number of diseases. It is possible to consider the translational medicine as a link between basic research and clinical practice, where a certain gap still exists, making the transition “bench to bedside” a reality. In this scenario, the innovations emerging in pharmaceutical, technological, and biomedical fields are increasingly numerous and valid, thus providing translational medicine with new effective weapons to enhance and facilitate the clinical practice.

The aim of this Special Issue is to discuss about innovative biomaterials (as such or following their transformation) or innovative application of biomaterials in translational medicine field. Both promising original scientific investigations and exhaustive reviews concerning this field are welcome.

Dr. Maria Cristiano
Prof. Dr. Massimo Fresta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • translational medicine
  • scaffold
  • biomaterials
  • drug targeting
  • in vivo studies
  • nanomedicine
  • precision medicine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 4067 KiB  
Article
Binary Mixtures of Meloxicam and L-Tartaric Acid for Oral Bioavailability Modulation of Pharmaceutical Dosage Forms
by Cristina Macasoi, Viorica Meltzer, Ioana Stanculescu, Cosmin Romanitan and Elena Pincu
J. Funct. Biomater. 2024, 15(4), 104; https://doi.org/10.3390/jfb15040104 - 16 Apr 2024
Viewed by 179
Abstract
Binary mixtures of active pharmaceutical ingredients (API) are researched to improve the oral bioavailability of pharmaceutical dosage forms. The purpose of this study was to obtain mixtures of meloxicam and L-tartaric acid because tartaric acid improves intestinal absorption and meloxicam is more soluble [...] Read more.
Binary mixtures of active pharmaceutical ingredients (API) are researched to improve the oral bioavailability of pharmaceutical dosage forms. The purpose of this study was to obtain mixtures of meloxicam and L-tartaric acid because tartaric acid improves intestinal absorption and meloxicam is more soluble in a weakly basic environment. The mixtures in the 0–1 molar fraction range, obtained from solvent-assisted mechanosynthesis, were investigated by differential scanning calorimetry (DSC), Fourier Transform Infrared (FTIR) spectroscopy, Fourier Transform Raman spectroscopy (FT-Raman), X-ray powder diffraction (XRD) and solubility tests. The physicochemical characteristics of the compounds obtained from DSC data reveal, for the first time, the formation of a co-crystal at meloxicam molar fraction of 0.5. FTIR spectroscopy data show the existence of hydrogen bonds between the co-crystal components meloxicam and L-tartaric acid. FT-Raman spectroscopy was used complementary with FT-IR spectroscopy to analyze the pure APIs and their mixtures, to emphasize the appearance/disappearance and the shifts of the position/intensity of vibrational bands, following the formation of hydrogen-bonded structures or van der Waals interactions, and to especially monitor the crystal lattice vibrations below 400 cm−1. The experimental results obtained by X-ray powder diffraction confirmed the formation of the co-crystal by the loss and, respectively, the apparition of peaks from the single components in the co-crystal diffractogram. The solubility tests showed that the co-crystal product has a lower aqueous solubility due to the acidic character of the other component, tartaric acid. However, when the solubility tests were performed in buffer solution of pH 7.4, the solubility of meloxicam from the co-crystal mixture was increased by 57% compared to that of pure meloxicam. In conclusion, the studied API mixtures may be considered potential biomaterials for improved drug release molecular solids. Full article
(This article belongs to the Special Issue Biomaterials for Translational Medicine)
►▼ Show Figures

Figure 1

16 pages, 4897 KiB  
Article
Long-Term Degradation Assessment of a Polyurethane-Based Surgical Adhesive—Assessment and Critical Consideration of Preclinical In Vitro and In Vivo Testing
by Lisanne Bremer, Kerstin Hagemeister, Michaela Moss, Lisa Ernst, René H. Tolba, Stefan Jockenhoevel and Christian Apel
J. Funct. Biomater. 2023, 14(3), 168; https://doi.org/10.3390/jfb14030168 - 21 Mar 2023
Cited by 4 | Viewed by 1575
Abstract
Tissue adhesives constitute a great possibility to improve conventional wound closure. In contrast to sutures, they enable nearly immediate hemostasis and can prevent fluid or air leaks. In the present study, a poly(ester)urethane-based adhesive was investigated which already proved to be suitable for [...] Read more.
Tissue adhesives constitute a great possibility to improve conventional wound closure. In contrast to sutures, they enable nearly immediate hemostasis and can prevent fluid or air leaks. In the present study, a poly(ester)urethane-based adhesive was investigated which already proved to be suitable for different indications, such as reinforcing vascular anastomosis and sealing liver tissue. Using in vitro and in vivo setups, the degradation of the adhesives was monitored over a period of up to 2 years, to evaluate long-term biocompatibility and determine degradation kinetics. For the first time, the complete degradation of the adhesive was documented. In subcutaneous locations, tissue residues were found after 12 months and in intramuscular locations, tissue degradation was complete after about 6 months. A detailed histological evaluation of the local tissue reaction revealed good biocompatibility throughout the different degradation stages. After full degradation, complete remodeling to physiological tissue was observed at the implant locations. In addition, this study critically discusses common issues related to the assessment of biomaterial degradation kinetics in the context of medical device certification. This work highlighted the importance and encouraged the implementation of biologically relevant in vitro degradation models to replace animal studies or at least reduce the number of animals in preclinical testing prior to clinical studies. Moreover, the suitability of frequently used implantation studies based on ISO 10993-6 at standard locations was critically discussed, especially in light of the associated lack of reliable predictions for degradation kinetics at the clinically relevant site of implantation. Full article
(This article belongs to the Special Issue Biomaterials for Translational Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop